Changes in Hong Kong stocks | Tongyuankang Pharmaceutical-B (02410) is now up more than 6% TYK-01054 capsules start phase I/II clinical indications for advanced solid tumors

The Zhitong Finance App learned that Tongyuankang Pharmaceutical-B (02410) is now up more than 6%. As of press release, it has risen 4.6% to HK$13.41, with a turnover of HK$20.881,400.

According to the news, data from the drug clinical trial registration and information disclosure platform shows that a phase I/II, open label, multicenter study from Zhejiang Tongyuankang Pharmaceutical Co., Ltd. to evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of the TEAD inhibitor TYK-01054 capsules in patients with locally advanced or advanced metastatic solid tumors has begun. The clinical trial registration number is CTR20255003, and the first public information date is December 26, 2025.

According to public information, TYK-01054 capsules are chemical drugs, and the indications are advanced solid tumors. Advanced solid tumors are tumors where cancer cells have spread to other parts of the body. Symptoms vary depending on the type of tumor, and commonly include pain and fatigue. Diagnosis relies on imaging tests, pathological biopsies, etc.